The use of Random Homozygous Gene Perturbation to identify novel host-oriented targets for influenza.

Conventional approaches for therapeutic targeting of viral pathogens have consistently faced obstacles arising from the development of resistant strains and a lack of broad-spectrum application. Influenza represents a particularly problematic therapeutic challenge since high viral mutation rates have often confounded many conventional antivirals. Newly emerging or engineered strains of influenza represent an even greater threat as typified by recent interest in avian subtypes of influenza. Based on the limitations associated with targeting virally-encoded molecules, we have taken an orthogonal approach of targeting host pathways in a manner that prevents viral propagation or spares the host from virus-mediated pathogenicity. To this end, we report herein the application of an improved technology for target discovery, Random Homozygous Gene Perturbation (RHGP), to identify host-oriented targets that are well-tolerated in normal cells but that prevent influenza-mediated killing of host cells. Improvements in RHGP facilitated a thorough screening of the entire genome, both for overexpression or loss of expression, to identify targets that render host cells resistant to influenza infection. We identify a set of host-oriented targets that prevent influenza killing of host cells and validate these targets using multiple approaches. These studies provide further support for a new paradigm to combat viral disease and demonstrate the power of RHGP to identify novel targets and mechanisms.

[1]  F. Bushman,et al.  Retroviral DNA Integration: ASLV, HIV, and MLV Show Distinct Target Site Preferences , 2004, PLoS biology.

[2]  J. Gerberding,et al.  Interim within-season estimate of the effectiveness of trivalent inactivated influenza vaccine--Marshfield, Wisconsin, 2007-08 influenza season. , 2008, MMWR. Morbidity and mortality weekly report.

[3]  Ruth R. Montgomery,et al.  RNA interference screen for human genes associated with West Nile virus infection , 2008, Nature.

[4]  R. König,et al.  Global Analysis of Host-Pathogen Interactions that Regulate Early-Stage HIV-1 Replication , 2008, Cell.

[5]  D. Evans,et al.  Apoptosis: a mechanism of cell killing by influenza A and B viruses , 1994, Journal of virology.

[6]  M. Katze,et al.  Systems biology and the host response to viral infection , 2007, Nature Biotechnology.

[7]  H. Tsuchie,et al.  Amino-terminal fragment of urokinase-type plasminogen activator inhibits HIV-1 replication. , 2001, Biochemical and biophysical research communications.

[8]  R. Lamb,et al.  Death by influenza virus protein , 2001, Nature Medicine.

[9]  Paul Ahlquist,et al.  Host Factors in Positive-Strand RNA Virus Genome Replication , 2003, Journal of Virology.

[10]  R. Lamb,et al.  Mechanisms for enveloped virus budding: can some viruses do without an ESCRT? , 2008, Virology.

[11]  J. Lieberman,et al.  Identification of Host Proteins Required for HIV Infection Through a Functional Genomic Screen , 2007, Science.

[12]  J. Wheeler,et al.  Assessing Theoretical Risk and Benefit suggested by Genetic Association Studies of CCR5: Experience in a Drug Development Programme for Maraviroc , 2007, Antiviral therapy.

[13]  Michael D. George,et al.  Expression of simian immunodeficiency virus Nef protein in CD4+ T cells leads to a molecular profile of viral persistence and immune evasion. , 2006, Virology.

[14]  M. Newton,et al.  Drosophila RNAi screen identifies host genes important for influenza virus replication , 2008, Nature.

[15]  S. Keay,et al.  Molecular cloning and expression of receptor peptides that block human cytomegalovirus/cell fusion. , 1996, Biochemical and biophysical research communications.

[16]  J. Fox Antivirals become a broader enterprise , 2007, Nature Biotechnology.

[17]  Keiji Fukuda,et al.  Mortality associated with influenza and respiratory syncytial virus in the United States. , 2003, JAMA.

[18]  Justine R. Smith,et al.  Sequence- and target-independent angiogenesis suppression by siRNA via TLR3 , 2008, Nature.

[19]  Michael T. McManus,et al.  RNA interference of influenza virus production by directly targeting mRNA for degradation and indirectly inhibiting all viral RNA transcription , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[20]  S. Murray,et al.  Mutation of a Ubiquitously Expressed Mouse Transmembrane Protein (Tapt1) Causes Specific Skeletal Homeotic Transformations , 2007, Genetics.

[21]  B. García-Barreno,et al.  Distinct gene subsets are induced at different time points after human respiratory syncytial virus infection of A549 cells. , 2007, The Journal of general virology.

[22]  S. Pleschka,et al.  A fatal relationship--influenza virus interactions with the host cell. , 1999, Viral immunology.

[23]  F. Hayden,et al.  John F. Enders lecture 2006: antivirals for influenza. , 2007, The Journal of infectious diseases.

[24]  John Calvin Reed,et al.  Conversion of lytic to persistent alphavirus infection by the bcl-2 cellular oncogene , 1993, Nature.

[25]  Stanley N Cohen,et al.  tsg101: A Novel Tumor Susceptibility Gene Isolated by Controlled Homozygous Functional Knockout of Allelic Loci in Mammalian Cells , 1996, Cell.

[26]  Hiroaki Kitano,et al.  The PANTHER database of protein families, subfamilies, functions and pathways , 2004, Nucleic Acids Res..

[27]  R. Varshney,et al.  Cereal Genomics: An Overview , 2004 .

[28]  Stanley N Cohen,et al.  EST-based genome-wide gene inactivation identifies ARAP3 as a host protein affecting cellular susceptibility to anthrax toxin. , 2004, Proceedings of the National Academy of Sciences of the United States of America.